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Abstract  This case report deals with a patient managed in a tertiary-care cancer hospital who suffered pruritus associated with malignant cholestasis. His symptoms were resistant to conventional treatment with ursodeoxycholic acid, chlorpheniramine and cholestyramine. Hence, the multifactorial origin of malignancy- associated pruritus was considered. Correctable factors were corrected and generally the treatment was aimed at possible aetiologies. There were barriers related to insufficient resources available for symptom palliation in this particular setting, which could potentially reduce optimum symptom control. However, various pharmacotherapies and non-pharmacological measures which could potentially have helped relieve pruritus are described and future scope for research in this area discussed.  
Background  ‘Pruritus’ or ‘itch’ is a sensory percep- tion which leads to the reflexive act of scratching. It is designated as a ‘nocicep- tive’ perception since pruritus likely arises from exogenous (eg, caustic substances) or endogenous (eg, histamine) noxious stimuli which are weaker in intensity than those which generate pain.1 In cholestasis, interruption of enterohepatic bile acid circulation results in sequestration under- neath the skin, an endogenous source of pruritogenic stimulation.  
Generally, pruritus is not a common cancer symptom.2 It is part of the Memo- rial Symptom Assessment Scale.3 Pruritus is more commonly associated with specific cancers such as Hodgkin’s lymphoma, leukaemia and myeloma.4 5 In 10% of instances, it is a paraneoplastic manifes- tation of malignancy.4 Pruritus may occur from the malignancy itself, resulting in cholestasis, renal failure from treat- ments like adverse reactions to opioids or targeted anti-cancer therapies.6 7  
A quarter of those with cholestasis experience distressing pruritus.8 Common  bile duct stenting is considered the gold- standard treatment associated in malignant cholestasis. In conservative management, ursodeoxycholic acid (stimulates hepa- tobiliary secretions) is recommended.5 9 Some evidence support the selective serotonin reuptake inhibitor (SSRI) anti- depressant sertraline as a safe, effective first-line therapy.10 Rifampicin can help, but the risk of hepatotoxicity, which could potentially worsen cholestasis, limits its use.11 The opioid-receptor antagonists butorphanol and naltrexone are not suit- able for those on opioids for symptom relief.12 13 Dronabinol, interferon-alpha, mirtazapine, phenobarbital, propofol, thalidomide and ursodeoxycholic acid are some other options.1  
Case presentation  The patient was a sexagenarian who suffered from progressive dysphagia and significant weight loss for over 2months before he presented to the hospital. He was diagnosed with advanced adenocarci- noma (stage T4b) in the lower third of the oesophagus, encroaching on the stomach. It was deemed unresectable. The tumour had metastasised to the lower lumbar distant nodes, liver and lumbar vertebrae (including the porta hepatis).  He received chemoradiation to palliate his dysphagia. Two weeks following the completion of radiotherapy, food intake had improved, with a weight gain of 4kg over the following month. He also suffered from backache, treated with ibuprofen plus omeprazole with satisfac- tory results.  Two months later, he was re-admitted with worsening anorexia, backache, jaun- dice, generalised pruritus and weakness. He was referred to the palliative care unit (PCU), where the following management strategies were employed. He had to be discharged after 2 days and managed as an outpatient due to bed shortage.  
Case assessment  
Investigations demonstrated cholestatic jaundice (total bilirubin of 80 μmol/L) and elevated serum bile 
salt levels (32 μmol/L) which were attributed to the porta- hepatis lymphadenopathy. Marginal hypercalcaemia (serum ionised calcium of 2.85mmol/L) and anaemia (haemoglobin=9 g/dL) were the identifiable causes for the constitutional symptoms like asthenia and anorexia (hypercalcaemia may also cause pruritus).8  Renal function was stable making uraemia a remote cause for pruritus. Possible iatrogenic causes for pruritus were ibuprofen and morphine (the latter was introduced at the initial visit).  
Case management  He was started on ursodeoxycholic acid on his initial visit. This is the first-line agent, with multiple mecha- nisms of action in cholestasis-related pruritus.8 9 This was combined with the oral antihistamine chlorphe- niramine. This was a good choice for two reasons: wide availability in the hospital and as a first- generation (sedating) antihistamine proven supe- rior to second-generation drugs (eg, loratadine) for pruritus.14 Cholestyramine was added due to inade- quate response in the follow-up visit 2weeks later. Notwithstanding cholestyramine’s ability to bind avidly with bile salts thus eliminating them from skin, there is evidence cholestyramine is often ineffective since the blood level of bile salts correlates poorly with clinical pruritus.15 16  The single definitive treatment of proven universal efficacy for pruritus from cholestasis is biliary drainage.8 Despite minimally invasive procedures such as endo- scopic ultrasonography or endoscopic retrograde chol- angiopancreatography, in our clinical setting with limited resources, patients with cancer do not have access to such sophisticated procedures, and further, the patient stressed his strong aversion towards invasive procedures.  Four pints of blood were transfused and meticulous rehydration done with intravenous 0.9% saline. Intra- venous bisphosphonate (etidronate) was administered as a single dose 7.5mg/kg along with high-dose dexa- methasone (24mg daily in four divided doses), which improved hypercalcaemia, and possibly the related constitutional symptoms and pruritus.17 Etidronate also potentially contributed towards the relief of back pain associated with vertebral metastasis.1 17  
Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), may cause allergy and hence pruritus.18 However, he tolerated the drug well over the previous 2 months.  
Oral morphine at the PCU visit was titrated to anal- gesic effect, and this had rendered him free of back pain by the second review without worsening pruritus.19 Since his pain was controlled with oral morphine, it was not prudent to try naltrexone for pruritus since it could exaggerate pain.  
Case Outcome  At his second review 2weeks later in the palliative care clinic, the back pain was still controlled. Fatigue had improved significantly, and his appetite returned. He was unconcerned by the yellowish discolouration of his skin and mucous membranes. The itching continued. He had been discharged from the inpatient facility by the oncology team without notifying the palliative team.  
Discussion  The 5-hydroxytryptamine (5-HT3) receptor antagonist ondansetron, which is of proven efficacy in alleviating pruritus due to cholestasis and sertraline (SSRI), would have been potential options. Parenteral lignocaine is effective for intractable cholestatic pruritus and is a widely available local anaesthetic.1 Other pharmaco- logical agents are efficacious to varying degrees. Incon- veniences in generalised itching has limited the use of bland emollients and levomenthol cream which have also been found to be effective. Non-pharmacological measures like acupuncture, plasma exchange, transcuta- neous electrical nerve stimulation (TENS) and ultravi- olet-B combined with crotamiton have shown variable promise.16  
Conclusions  Malignant cholestasis–associated pruritus can be a trou- blesome symptom. Therapeutic use of ursodeoxycholic acid combined with antihistamines may fail to relieve the symptom sufficiently. Even though cholestyramine in the standard management of cholestatic pruritus is common in this clinical setting, it is less predictable. Pruritus in malignancy may also be complicated by factors like NSAIDs, opioids or metabolic derangements such as uraemia and hypercalcaemia, which also need to be addressed.  A growing knowledge base on alternative pharma- cological and non-pharmacological treatments brings optimism about the future management of pruritus associated with malignant cholestasis. 5-HT3 receptor antagonists, SSRIs, lignocaine, levomenthol, TENS, acupuncture, plasma exchange and UV+crotamiton are among these novel therapeutic modalities.  
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